Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown promising preliminary data in lung cancer with impressive response rates and survival outcomes in previously treated patients.There are several ADCs currently in clinical trials for NSCLC and small cell lung cancer (SCLC). These ADCs often have different targets which include HER2, HER3, TROP2, CEACAM5, and MET in NSCLC and DLL3 in SCLC.Here we review the safety, and efficacy of newer ADCs in lung cancer including ado-trastuzumab emtansine, trastuzumab deruxetecan, patritomab deruxetecan, datopotamab deruxetecan, sacituzumab govitecan, SAR408701, Telisotuzumab vedotin, rovalpituzumab tesirine, lorvotuzumab mertansine, and sacituzumab govitecan. Several novel methods are underway to improve the safety and efficacy of ADCs which include increasing the drug to antibody ratio (DAR), the potency of the payload, using more innovative payloads and replacing the antibody.

almost 3 years ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CEACAM5 (CEA Cell Adhesion Molecule 5) • DLL3 (Delta Like Canonical Notch Ligand 3)

Kadcyla (ado-trastuzumab emtansine) • Trodelvy (sacituzumab govitecan-hziy) • tusamitamab ravtansine (SAR408701) • telisotuzumab vedotin (ABBV-399) • Rova-T (rovalpituzumab tesirine) • lorvotuzumab mertansine (IMGN901)

almost3years

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (clinicaltrials.gov)

P2, N=62, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021

almost 3 years ago

Clinical • Trial completion • Trial completion date

NCAM1 (Neural cell adhesion molecule 1)

NCAM1 expression

lorvotuzumab mertansine (IMGN901)

over4years

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. (PubMed, Cancer)

Lorvotuzumab mertansine (110 mg/m ) is tolerated in children at the adult recommended phase 2 dose; clinical activity is limited.

over 4 years ago

Clinical • P2 data • Journal

NCAM1 (Neural cell adhesion molecule 1)

dexamethasone • lorvotuzumab mertansine (IMGN901)